Article

Liquefaction device assures safe, gentle lens removal

New Orleans-The AquaLase liquefaction device (Alcon) is a new technology for lens removal that provides the advantages of excellent safety for the cornea and posterior capsule without sacrificing efficiency, said Stephen F. Brint, MD.

Related Videos
Image credit: ©Ophthalmology Times
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
Related Content
Image credit: Mercy Ships
February 4th 2025

Mercy Ships delivers a lifeline for eye health in Africa’s remote communities

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Playing matchmaker with Schlemm canal surgery
December 30th 2024

Playing matchmaker with Schlemm canal surgery

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Multidisciplinary team secures multimillion-dollar award to fund research to achieve a functional human eye transplant
December 3rd 2024

Multidisciplinary team secures multimillion-dollar award to fund research to achieve a functional human eye transplant

Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
November 20th 2024

Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300

© 2025 MJH Life Sciences

All rights reserved.